JetBlue Adds Business-Class Cabin: Ahead of the Ticker

NEW YORK ( TheStreet) -- All-coach airline JetBlue Airways ( JBLU) announced it is adding a business-class cabin that will include 16 lie-flat seats on flights between New York and Los Angeles and San Francisco.

The 16 premium seats will include air cushions with adjustable firmness and massage capabilities, a 15-inch television and a "wake-me-for-service" flight-attendant indicator. They will measure 6 feet, 8 inches when reclined into full, lie-flat position. Four of the 16 seats will have doors and will be dubbed "private suites." JetBlue said 11 of its new Airbus A321 planes will feature the seats in the second quarter of 2014. Planes that include the new seats will accommodate 143 passengers in coach.

JetBlue hasn't yet announced the price of the new premium seats.

Competitors United Airlines ( UAL), American Airlines and Delta Air Lines ( DAL) have all been implementing seats that can fully recline on their transcontinental flights.

Billionaire investor Carl Icahn increased his stake in Dell ( DELL) as a shareholder vote over control of the company approaches.

Icahn disclosed in a regulatory filing late Monday that he purchased an additional 4 million shares in Dell on Thursday, bringing his stake in the company to 8.9% from 8.7%. Icahn purchased the shares on the same day he filed a suit to block a delay in a shareholder vote over control of the company.

Founder Michael Dell and investment firm Silver Lake Partners boosted their buyout bid for the company just one day later. Their bid is currently $13.75 a share, with shareholders receiving a special dividend of 13 cents share. A shareholder vote on the offer is scheduled for Sept. 12.

Icahn has bid $15.50 a share.

Drugstore chain CVS Caremark ( CVS) reported a 16% rise in second-quarter profit that beat Wall Street expectations, driven by new generic drugs, which helped to boost operating profit in pharmacy units.

CVS earned $1.12 billion, or 91 cents a share, during the quarter, up from $966 million, or 75 cents a share, in the same period last year.

Adjusted earnings rose to 97 cents a share from 81 cents, beating analysts' expectations for earnings of 96 cents, according to Thomson Reuters.

Revenue climbed 1.7% to $31.25 billion.

"As expected, new generic drug introductions continued to be a significant growth driver across the enterprise, resulting in healthy margin expansion and earnings growth," President and CEO Larry Merlo said in a statement.

The company also narrowed its 2013 earnings per share forecast. It now expects adjusted earnings of $3.90 to $3.96 a share for the full year. Analysts have expected a full-year profit of $3.98. CVS narrowed its guidance in accordance with the timing of share repurchases.

The chatter on Main Street (a.k.a. Google, Yahoo! and other search sites) is always of interest to investors on Wall Street. Thus, each day, TheStreet compiles the stories that are trending on the Web, and highlights the news that could make stocks move.

-- Written by Brittany Umar.
Brittany joined TV in November 2006 after completing a degree in Journalism and Media Studies at Rutgers College. Previously, Brittany interned at the local ABC affiliate in New York City WABC-TV 7 where she helped research and produce On Your Side, a popular consumer advocacy segment.